M&A Deal Summary |
|
|---|---|
| Date | 2015-10-21 |
| Target | Vree Health |
| Sector | Information Technology |
| Buyer(s) | PatientSafe Solutions |
| Sellers(s) | Merck Sharp & Dohme B.V. |
| Deal Type | Divestiture |
SEARCH BY
PatientSafe Solutions consolidates secure messages, voice calls, alerts, and nurse call notifications with data from the electronic medical record (EMR) to enable care teams to quickly manage mission-critical workflows in one mobile smartphone app. PatientSafe Solutions is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Information Technology M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). Merck Sharp & Dohme B.V provides medicines for diabetes, High blood pres pressure and rheumatic disease patients.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Information Technology M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 3 of 3 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-02 |
Saphris
United States Saphris is approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults, and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as monotherapy or as adjunctive therapy with either lithium or valproate. |
Sell | $240M |
